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Progressive ventricular hypertrophy can lead to the
development of insulin resistance, a feature of both chronic
kidney disease and heart failure. Here we induced uremia in
adult male Sprague-Dawley rats using a remnant kidney
model and studied the expression of glucose transporters. As
expected, the reduction of nephron mass resulted in
impaired renal function, cardiac hypertrophy, glucose
intolerance, hyperinsulinemia, anemia, and hypertension.
Insulin sensitivity was significantly reduced in the uremic
animals as determined by oral glucose tolerance tests. After
six weeks of uremia, at a point when cardiac hypertrophy had
been established, left ventricle tissue had a marked increase
in the expression of GLUT4 (insulin-dependent glucose
transporter 4), consistent with hypertrophic remodeling, but
not GLUT1 (insulin-independent glucose transporter 1).
However, although uremic animals had systemic insulin
resistance and glucose intolerance, there was no evidence of
impaired GLUT4 translocation in the heart at 6 weeks of
uremia, suggesting that other mechanisms may underpin
insulin resistance in the uremic heart.
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Chronic kidney disease (CKD) is one of the most prevalent
pathologies in the Western world.1 Cardiac complications are
a major cause of morbidity and mortality in CKD patients,
with insulin resistance and hyperinsulinemia present at
the early stages of renal dysfunction.2,3 Insulin resistance is
an independent predictor of cardiovascular mortality in
uremia.4–6 CKD is accompanied by a number of confounding
factors, including left ventricular hypertrophy (LVH),
anemia, myocardial contractile dysfunction, and insulin
resistance, resulting in significant myocardial cellular and
structural remodeling.7 LVH can be characterized by meta-
bolic remodeling, with a switch in substrate preference from
fatty acid oxidation to glucose utilization. This adaptation
highlights a re-expression of the fetal phenotype, conse-
quently causing increased reliance on glucose for energy
generation.8 However, in the long term, this alteration may
be detrimental, as the progression of LVH can result in the
development of insulin resistance through impaired meta-
bolic substrate transport by the two glucose transporters 1
and 4 (GLUT1 and GLUT4).9–12 In this setting, glucose
uptake would be reduced causing the hypertrophied heart to
spiral into energy starvation and heart failure. GLUT4 is the
insulin-sensitive transporter.13 Upon insulin stimulation,
GLUT4 is translocated to the plasma membrane where it
facilitates the uptake of glucose.14 Insulin resistance may arise
as a consequence of impaired signaling, alteration in
transporter expression, or transporter translocation.15–17
The aim of this study was to examine myocardial insulin
resistance and the underlying changes in the expression of
glucose transporters in uremia as a model of cardiac
hypertrophy.
RESULTS
Morphological characteristics of the uremic model
Animals exposed to 6 weeks of uremia were characterized by
marked hemodynamic abnormalities, including elevated
systolic and diastolic pressures (Po0.01) and heart rate
(Po0.01) (Table 1). A significant degree of hypertrophy
(LVH) was apparent in the uremic ventricle, indicated by an
increased ratio of dry heart weight to tibia length (Table 1).
Consistent with this finding, there was a significant increase
in the LV atrial natriuretic factor (ANF) expression in 6-week
uremic vs 6-week control groups (optical density: 1.12±0.01
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vs 0.05±0.01, Po0.05; data not shown). LVH was also
apparent in uremic cardiomyocytes, characterized by a
significant increase in the cell width (35.2±0.6 vs
32.5±0.6 mm, n¼ 287 cells, n¼ 5 hearts; Po0.05 vs control).
Renal impairment was evident from the marked increase in
the serum creatinine concentration (Po0.01) (Table 2).
Uremic animals were characterized by an 18% reduction in
blood hematocrit (Po0.01) and hyperinsulinemia (Po0.05),
but with no alteration in serum glucose, fatty acids, or lactate
concentrations, consistent with earlier observations.18
Three-week uremia was characterized by a significant renal
impairment (serum creatinine: 60.7±3.2 vs 40.0±4.9 mmol/
l; n¼ 5 Po0.05), hypertension (systolic pressure: 145.4±3.4
vs 132.3±4.2 mm Hg; diastolic pressure: 94.3±2.2 vs
85.9±2.7 mm Hg, n¼ 11, Po0.05), and normoinsulinemia
(1.1±0.1 vs 1.2±0.1 mg/l, n¼ 3). There was no evidence of
cardiac hypertrophy (LVH), with no change in the ratio of
dry heart weight to tibia length (0.37±0.01 vs 0.35±0.01 g/
cm, n¼ 5) or the expression of ANF (optical density:
0.08±0.02 vs 0.05±0.01).
After nine weeks of uremia, animals exhibited significant
uremia (creatinine: 91.3±3.6 vs 43.1±2.1mmol/l, n¼ 9
Po0.05), hypertension (systolic pressure: 142.2±2.3 vs
135.6±2.4 mm Hg; diastolic pressure: 93.7±1.7 vs 89.3±1.8;
n¼ 8 Po0.05), hypertrophy (dry heart weigh/tibia length:
0.38±0.02 vs 0.32±0.01 g/cm, n¼ 8 Po0.05), and hyper-
insulinemia (2.2±0.4 vs 1.2±0.2mg/l, n¼ 8 Po0.05).
Oral glucose tolerance test
Six-week uremic animals were significantly hyperglycemic
and hyperinsulinemic in comparison with controls at 90 min
after administration of glucose load (as shown in Figure 1).
The glucose challenge also produced a marked increase in
serum insulin in control animals at both 30 and 60 min in
comparison with the fasting levels. In contrast, uremic
animals were hyperinsulinemic in the fasting state compared
with controls (Figure 1b), reaching peak insulin concentra-
tions only at 120 min, however, without a significant increase
above the uremic fasting insulin levels (Po0.05 vs fasting
state) (Figure 1b). The index of insulin resistance, home-
ostasis model assessment-insulin resistance (HOMA-IR), was
significantly higher in uremic animals than that in controls
(1.27±0.3 vs 0.58±0.1, Po0.02) (Figure 2). By 9 weeks,
uremic animals exhibited hyperglycemia at 30, 60, and
Table 2 | Serum analysis
Characteristic Uremic (n=26) Control (n=26)
Creatinine (mmol/l) 69.7±2.1a 40.3±2.1
Urea (mmol/l) 15.5±0.4a 6.4±0.4
Hematocrit (%) 27.9±0.9a 34.0±1.1
Insulin (mg/l) 2.05±0.2b 1.48±0.1
Proinsulin (pmol/l) 151.8±7.8b 132.05±5.6
aPo0.01 vs control.
bPo0.05 vs control.
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Figure 1 | Glucose and insulin responses to an oral glucose
challenge at 6 weeks uremia. (a) Glucose and (b) insulin
responses to an oral glucose challenge in 6 weeks uremia. Values
are mean±s.e.m. for n¼ 8, **Po0.05 vs control.
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Figure 2 | HOMA-IR index for control and 6-week uremia.
Values are mean±s.e.m. for n¼ 8, **Po0.02 vs control.
Table 1 | Characteristics of 6-week experimental uremia
Characteristic Uremic (n=26) Control (n=26)
Systolic blood pressure (mm Hg) 162.7±1.5a 146.9±1.7
Dry heart weight/tibia length (g/cm) 0.45±0.01b 0.38±0.01
Dry heart weight (g) 2.13±0.07b 1.94±0.05
Diastolic blood pressure (mm Hg) 106.3±1.0a 95±1.1
Heart rate in vivo (b.p.m.) 283.7±3.2a 269.1±2.8
aPo0.01 vs control.
bPo0.05 vs control.
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120 min after glucose ingestion (Figure 3a) and hyperinsu-
linemia up to 120 min (30, 60, and 90 min) (Po0.05 vs
control serum glucose and serum insulin; Figure 3b).
HOMA-IR was significantly higher in 9-week uremic animals
than in controls (7.2±4.0 vs 1.87±0.7; Po0.05) and
increased compared with 6 weeks uremia (72%, Po0.05).
GLUT4 expression and translocation in isolated
cardiomyocytes
GLUT4 was translocated to the cardiomyocyte surface in
response to the insulin stimulation, as observed from the
prominent GLUT4-specific fluorescence cell surface labeling
(Figure 4a and b). In the absence of insulin, GLUT4 was
located in the intracellular compartments (Figure 4c and d).
Cardiomyocytes isolated from uremic animals expressed
considerably higher GLUT4 content in the presence and
absence of insulin than in control cells, as observed from the
quantification of fluorescence corresponding to labeled
GLUT4 (Po0.01).
Glucose transporter cardiac expression
After 6 weeks, uremic LV tissue expressed a higher GLUT4
content than control LV tissue (Po0.05) (Figure 5a).
This was not observed in 3- and 9-week uremic animals
(data not shown). GLUT1 levels were not altered at any stage
of uremia studied (3, 6, or 9 weeks) (Figure 5b). In contrast,
the 6-week GLUT4 skeletal muscle expression was markedly
reduced in uremic animals compared with control animals
(Figure 6).
GLUT4 subcellular distribution
Under basal conditions, GLUT4 was primarily located in the
intracellular membrane compartments in both groups
(Figure 7a). The GLUT4 measurements of the total
membrane fraction were 30% higher in uremic hearts than
in control hearts (Figure 7b) and 20% higher in intracellular
fractions (Figure 7a), whereas the GLUT4 content of
sarcolemma was reduced by 36% in 6 weeks uremia.
However, the differences were not statistically significant.
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Figure 3 | Glucose and insulin responses to an oral glucose
challenge in 9 weeks uremia. (a) Glucose and (b) insulin
responses to an oral glucose challenge in 9 weeks uremia. Values
are mean±s.e.m. for n¼ 6, **Po0.05 vs control. Figure 4 | GLUT4 immunofluorescence in the presence or
absence of insulin in isolated cardiomyocytes. (a) GLUT4
fluorescence in uremic cardiomyocytes incubated in the presence
of 1.0mM insulin. (b) GLUT4 fluorescence in control
cardiomyocytes incubated in the presence of 1.0 mM insulin.
(c) GLUT4 fluorescence in uremic cardiomyocytes incubated in the
absence of insulin. (d) GLUT4 fluorescence in control
cardiomyocytes incubated in the absence of 1 mM insulin.
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DISCUSSION
This study has shown that after 6- and 9-week uremia, there
is clear evidence of insulin resistance in situ. Furthermore, it
has shown that the mechanism of myocardial insulin
resistance in uremia is not because of decreased GLUT4
expression or impaired translocation but more likely because
of less functional transporter activity.
Oral glucose tolerance
Uremic animals are characterized by marked glucose
intolerance and hyperglycemia 90 min after a glucose
load (Figure 1). Impaired oral glucose tolerance and home-
ostasis model assessment methods confirmed the reduction
in insulin sensitivity in uremic vs control animals
(Figure 2).19
Glucose intolerance and insulin resistance in uremia are
consistent with earlier observations in the experimental
models of hypertrophy.20 Clinical and experimental studies
have indicated that renal failure leads to a reduction in
systemic insulin removal because the kidneys play a major
role in the clearance and degradation of circulating
insulin.21,22 Therefore, the marked hyperinsulinemia
observed in the uremic group here can be attributed, in
part, to the impaired renal function in addition to the
presence of LVH. Fliser et al.,23 in a clinical study at different
stages of renal failure, found that insulin insensitivity and
hyperinsulinemia were present from the early phase of renal
dysfunction and in all CKD patients irrespective of the
primary etiology of the renal failure. The evidence of insulin
resistance in this experimental model of uremia is consistent
with these clinical observations.24
Indeed, a significant positive correlation between serum
creatinine and serum insulin (two-tailed Pearson’s correlation
coefficient: r¼ 0.438; coefficient of determination: r2¼ 0.192;
n¼ 26, Po0.02) and between serum creatinine and HOMA-
IR (two-tailed Pearson’s correlation coefficient: r¼ 0.461;
coefficient of determination: r2¼ 0.212; n¼ 26, Po0.01) was
observed, indicating that the severity of renal impairment
correlated with hyperinsulinemia. This implies that the
decline in renal function may be associated with a progressive
deterioration in global insulin sensitivity and increasing
hyperinsulinemia. These findings highlight the continuing
detrimental effect of renal dysfunction on the development of
insulin resistance. Thus, the experimental uremic model used
in this study provides a viable model, representative of CKD.
Metabolic transporter expression and LVH
Total cellular GLUT4 content of the LV is significantly
increased, irrespective of the presence of insulin in the media
(Figure 4). This was further confirmed by the increased
GLUT4 protein content in left ventricular tissue and total
membrane fraction. Subcellular fractionation of the left
ventricle (Figure 7a) showed that, in spite of increases in the
total GLUT4 content, there was no significant difference in
the distribution of GLUT4 in uremic vs control groups. This
suggests that there was no alteration in the translocation of
the GLUT4 to the sarcolemma under basal conditions unlike
the situation observed in a transgenic model of GLUT4
overexpression, characterized by higher plasma-membrane
GLUT4 protein concentration in the basal state, yet
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Figure 5 | Left ventricular glucose transporter expression at 6
weeks uremia. Representative immunoblots showing (a) GLUT4
and (b) GLUT1 expression in LV tissue from uremic and control
hearts 6 weeks after the induction of the experimental model.
Optical density measurements are mean±s.e.m. (of GLUT4, n¼ 9
and GLUT1, n¼ 5); **Po0.05 vs control.
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Figure 6 | GLUT4 expression in 6-week skeletal muscle. Optical
density measurements are mean±s.e.m. of n¼ 3, **Po0.01 vs
control.
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diminished GLUT4 translocation compared with controls.25
Supporting these findings was the lack of change in GLUT1
expression in both experimental groups, which indicated
normal insulin-independent glucose uptake.
Confocal microscopic studies have shown that GLUT4 can
be readily translocated with no impairment in the transporter
recruitment. This suggests that the insulin resistance in
uremia is not a result of abnormal GLUT4 translocation. A
reduction in the transporter activity may account for the
greater impairment in myocardial insulin-mediated glucose
uptake in uremia rather than dysfunctional GLUT4 translo-
cation, as is observed in soleus and triceps surae muscles.25,26
An increase in the myocardial GLUT4 expression in uremia
suggests an adaptive response to a limitation in the GLUT4
transport capacity and is typical of the reversion from an
adult to a fetal metabolic phenotype.
There is a clear evidence of hypertension from the earliest
stages of uremia (3 weeks), indicative of pressure overload
and a consequence of an activated program of embryonic
gene expression.27,28 Increased myocardial GLUT4 expression
in uremia is more suggestive of LVH rather than insulin
resistance.10,15,16 LVH is a hallmark of CKD and its severity
progresses with renal function deterioration.29 The uremic
cell morphology and the change in cardiomyocyte width, in
addition to the changes observed at the cellular protein level
(elevated LV ANF expression), highlight an increase in the LV
wall thickness that is typical of pressure overload LVH
development.
However, increased total GLUT4 protein expression does
not necessarily translate to functioning transporter activity.
Post-translational modification may modulate the activity of
GLUT4 and render it less active. Uremia is associated with
in vivo urea-derived cyanate carbamoylation of proteins
involved in signal transduction and translocation of GLUT4,
resulting in the reduction of protein activity.30
A potential cause of altered GLUT4 function could be
another form of post-translational protein alteration, such
as increased O-linked N-acetylglucosamine modification
identified in uremic hearts.31,32 Furthermore, the 13C-NMR
spectroscopic analysis of myocardial oxidative metabolism at
6-week uremia18,33 has shown no change in glucose
utilization, as would be anticipated from an increase in
GLUT4 expression and a predicted consequent increase in
glucose uptake, strongly suggesting altered GLUT4 activity.
Nevertheless, the potential of altered GLUT4 function by
post-translational modifications merits further investigation.
This study has provided evidence of systemic insulin
resistance in uremia through the reduction in skeletal muscle
GLUT4 expression, consistent with clinical studies in CKD
patients,34,35. The hyperinsulinemia observed here both in
vitro and in vivo results from a lowering in insulin sensitivity
in addition to the reduced renal insulin clearance and
degradation. It still remains to be determined whether
myocardial insulin resistance has specific/individual char-
acteristics that are distinctly mechanistically separate from
skeletal muscle insulin resistance.35
Increased serum insulin has been shown to increase the
rate of protein synthesis and decrease the rate of protein
degradation.36 Hence, hyperinsulinemic stimuli could con-
tribute further to alterations in GLUT4 expression. Clinical
studies have shown that a deterioration in systemic insulin
sensitivity and renal dysfunction increases the risk from
cardiovascular mortality.37 It has been suggested that the
presence of hyperinsulinemia may further exert adverse
effects on the vasculature, as HOMA-IR is independently
associated with carotid plaque formation, increased carotid
media thickness, and subsequently cardiovascular
events.6,38–40
Conclusion
This novel study has characterized experimental uremia by
morphological LVH and functional hemodynamic alterations
using integrated in vivo and in vitro approaches. It has shown
the presence of systemic insulin resistance and glucose
intolerance despite an increase in myocardial GLUT4
expression. These findings suggest that the mechanism
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underlying myocardial insulin resistance in uremia is most
likely post-translational protein modification, resulting in
altered transporter functionality/activity, an area that
requires further study.
Study limitations
Uremic cardiomyopathy is a specific form of heart disease.
This makes comparisons between experimental uremia and
other models of hypertrophy challenging, as any findings in
uremia are characteristic of a particular stage of the disease
process in the presence of a number of confounding variables
(for example, anemia, hyperparathyroidism, and hyper-
homocysteinemia). Therefore, the results presented in this
study are characteristic of a 6-week stage of uremia. Further
progression of the disease may cause additional alterations to
the cellular mechanism of myocardial insulin resistance.
The milieu of uremic toxins remains largely unknown,
and investigating the specific factors influencing the findings
will require more extensive study to identify potential uremic
retention solutes that may have a direct effect on cellular
insulin resistance in the setting of uremia.
MATERIALS AND METHODS
Experimental model
Chronic experimental uremia was induced surgically in male
Sprague–Dawley rats weighing on average 230 g (Charles River,
Kent, UK) through a two-stage 5/6 nephrectomy.18 All surgical
procedures were performed in accordance with the UK Home Office
Guidance on the Operation of the Animals (Scientific Procedures)
Act 1986 using aseptic techniques. At 24 h after the second
procedure, animals were housed individually and pair fed. Rats
were weighed weekly and had unlimited access to water. At 3, 6, and
9 weeks after surgical intervention, systolic blood pressure in
conscious animals was measured using a tail plethysmograph
(Harvard Apparatus, Kent, UK).18
The oral glucose tolerance test was based on the methods
described earlier20 and performed at 6- and 9-week uremia. Three-
week uremia was not assessed, as hyperinsulinemia was not
observed. In brief, animals were fasted overnight and glucose was
administered (6 g/kg body weight) through an oral gavage.
Blood (B5 ml) was collected through a tail venepuncture at 30,
60, 90, and 120 min after glucose administration. Serum glucose
concentrations were subsequently analyzed using ACCU-CHECK
Advantage Plus Test Strips and a digital monitor (Roche
Diagnostics, Penzberg, Germany). Serum samples were collected
and stored at 20 1C for the analysis of insulin concentration.
Insulin resistance was assessed using the homeostasis model
assessment (HOMA-IR),41 calculated using the following formula:
HOMA-IR (mmol/l mU/ml)¼ fasting glucose (mM) fasting in-
sulin (mU/ml)/22.5.
In addition to its use in clinical studies, the use of HOMA-IR in
rodents to assess insulin sensitivity has been validated in a number
of recent studies.42,43 At 3, 6, and 9 weeks after surgery, animals were
anesthetized with sodium thiopentone (100 mg/kg body weight,
i.p.). Hearts were rapidly excised and rinsed in the retrograde
Langendorff mode with the Krebs–Henseleit buffer (containing
(mM): 118 NaCl, 25 NaHCO3, 1.2 KH2PO4, 4.8 KCl, 1.2 MgSO4,
1.25 CaCl2, and 5 glucose; Sigma-Aldrich, Poole, UK), equilibrated
with 95% O2/5% CO2, pH 7.4, to remove residual blood. Right
ventricular tissue was dissected from the left ventricular tissue and
freeze-clamped separately.
Serum analysis
Blood samples were collected from the inferior vena cava before
excision of the heart, centrifuged (2700 g at 4 1C for 10 min) and
analyzed for insulin and pro-insulin concentrations using ultra-
sensitive rat-specific insulin and pro-insulin ELISA kits (Mercodia,
Uppsala, Sweden). Hematocrit was assessed using an ABL 77 blood
gas analyzer (Radiometer, Sussex, UK), and serum samples were
analyzed for urea and electrolytes by the Clinical Chemistry
Department at Hull Royal Infirmary. Serum metabolite concentra-
tions were determined using kits from Sigma-Aldrich, Poole, UK
(fatty acids kit no. 1383175) and Roche Diagnostics, Penzberg,
Germany (triglyceride kit no. 336) or spectrophotometric assays
(glucose and lactate), as described earlier.44
Ventricular myocyte isolation
Cardiomyocytes were isolated 6 weeks after surgery by collagenase
digestion, as described earlier.45 Dimensions of intact cardiomyo-
cytes were examined using a Leitz LaborLuxS light microscope
(Leica, Milton Keynes, UK), with  40 magnification lens connected
through a Cool SNAP-PRO digital camera to Image-Pro Plus
(v 5.1.2 software; Media Cybernetics, Bethesda, MD, Silver Spring,
USA). Cells were incubated in the presence or absence of 1 mM
insulin (Sigma-Aldrich) in K–H buffer (4% bovine serum albumin,
pH 7.4), for 1 h at 371C and 100% O2; fixed (4% paraformaldehyde
in PBS (phosphate-buffered saline) (w/v); Sigma-Aldrich) for
20 min at 37 1C and permeabilized for 45 min with 1% Triton
X-100 in PBS (v/v). Cells were probed with 2 mg/ml of monoclonal
GLUT4 antibody (AbD Serotec, Oxford, UK) and visualized with
4 mg/ml of FITC-conjugated goat IgG antibody (Molecular Probes,
Leiden, The Netherlands) using a Bio-Rad confocal system fitted to
a Nikon Eclipse TE 8000-E Radiance laser scanning 2100 system
microscope with  60 lens.
Cell images were collected using Zeiss Lasersharp 2000 software
and fluorescence intensity was quantified in Image Pro-Plus (v 5.1.2
software).
Protein expression analysis
Expressions of myocardial GLUT1 and GLUT4 were investigated
using SDS-PAGE and western blotting, as described earlier.46–48
In brief, cardiac ventricular samples were homogenized in lysis
buffer (50 mM of Tris, pH 7.4, 1 mM of phenylmethylsulfonyl
fluoride, mini-protease inhibitor cocktail tablets (Roche Diagnos-
tics) and centrifuged at 10 200 g for 10 min at 4 1C. The resulting
pellet was analyzed for protein using a Bio-Rad assay (Bio-Rad
Laboratories, Munchen, Germany), and diluted with Laemmli
solution containing 25 ml of 5% 2-mercaptoethanol.49 A total of
25 mg (GLUT1) or 40 mg (GLUT4) were separated on 10% SDS-
PAGE gels. Membranes were blocked with 7.5% (GLUT1) and 5%
(GLUT4) of non-fat milk powder (Marvel) in PBS, pH 7.6, and
0.02% of Tween 20 and probed with appropriate antibodies (GLUT1
goat polyclonal IgG (1:2000, Santa Cruz Biotechnology, Santa Cruz,
CA, USA), GLUT4 mouse monoclonal 1F8 clone (1:3000, AbD
Serotec) and secondary antibodies (donkey anti-goat (Santa Cruz
Biotechnology) and GLUT4 rabbit-anti mouse (AbD Serotec)). ANF
expression was analyzed as described earlier.48 Membranes were
visualized using an enhanced chemilumuinescence technique (ECL)
kit (Amersham, Little Chalfont, Buckinghamshire, UK) and
quantified with Image Pro-Plus (software v 5.1.2).
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Subcellular GLUT4 distribution
Intracellular distribution of GLUT4 was assessed by differential
sucrose gradient centrifugation.50 In brief, ventricular tissue was
homogenized in a sucrose (250 mM), NaHCO3 (10 mM), NaN3
(5 mM) buffer, pH 7.6, and centrifuged at 1200 g for 10 min.
The resulting pellets were re-suspended in homogenization
buffer and homogenized for 15 s. The resulting supernatant was
centrifuged for 1 h in a Beckman L8-80M ultracentrifuge at
190,000 g at 4 1C (Beckman Coulter, Paolo Alto, CA, USA) and
the pellets were re-suspended in 25% of sucrose solution. A volume
of 100 ml aliquots was taken for the total membrane analysis, and the
remaining was loaded onto a discontinuous sucrose gradient
consisting of 25 and 35% sucrose solution.
Sarcolemma and sarcoendoplasmic reticulum fractions were
separated using a Beckman ultracentrifuge swing-out rotor at
150,000 g at 4 1C for 20 h. Fractions were characterized using
NaþKþATPase expression as a marker for sarcolemma mem-
branes.51 GLUT4 protein expression was analyzed using SDS-PAGE
and western blotting as described above.
Statistical analysis
Data are expressed as mean±s.e.m. Unpaired Student’s t-test was
used for statistical analysis. All hypotheses tested are to be
conducted at the 0.05 level of significance.
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